Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Antibiotics Incentives List Goes Beyond GAIN Act

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency’s proposed rule on qualifying pathogens is longer than the initial legislative list, but industry still awaits regulations on the law’s exclusivity bonus, which are only achieved through a separate qualified disease product designation.

Advertisement

Related Content

Singapore’s Merlion Seeks Further Licensing Deals After Bolster By U.S. FDA Fast-Track Status
Antibiotic Resistance Gets Attention Of FDA, Congress
GAIN Begins (Part 1): FDA Completes Turnaround On Antibiotic R&D
PDUFA Negotiations: REMS Mud-Slinging, Supply Chain Compromising, GAIN Diminishing?

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075808

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel